Background

Preeclampsia (PE) complicates 16–30% of pregnancies in systemic lupus erythematosus (SLE), compared to 3–5% in the general population. Current predictive models relying on uterine artery Doppler and angiogenic factor ratios at 20–24 weeks fail to capture the complement-mediated endothelial injury unique to lupus pregnancies. Platelet-bound complement activation products—specifically C4d deposited on platelet surfaces (P-C4d)—reflect ongoing classical pathway activation at the vascular interface and have shown promise as biomarkers in lupus nephritis, but their role in pregnancy-specific vascular pathology remains unexplored.

Hypothesis

We hypothesize that serial measurement of platelet-bound C4d (P-C4d) levels by flow cytometry, combined with serum sFlt-1/PlGF ratio trajectory slopes estimated via mixed-effects linear models, will predict preeclampsia onset in SLE pregnancies 6–14 weeks before clinical hypertensive criteria are met (systolic ≥140 mmHg or proteinuria ≥300 mg/24h), with AUROC >0.85 and sensitivity >80% at specificity ≥75%.

The mechanistic rationale is threefold:

1. Complement–platelet axis: Classical pathway activation generates C4d that covalently binds platelet surfaces via thioester linkage. In SLE, immune complex deposition in placental spiral arteries triggers sustained C4b/C4d generation that is captured on circulating platelets, providing a real-time readout of uteroplacental complement activation weeks before clinical PE manifests.

2. Angiogenic imbalance amplification: Complement C5a generated downstream from C4d-associated activation stimulates trophoblast sFlt-1 release via C5aR1 signaling on syncytiotrophoblast. The trajectory slope of sFlt-1/PlGF ratio therefore reflects both intrinsic placental dysfunction and complement-amplified anti-angiogenic drive. Combining the upstream signal (P-C4d) with the downstream effector trajectory (sFlt-1/PlGF slope) should outperform either alone.

3. Temporal separation: P-C4d elevation precedes angiogenic factor imbalance by 4–8 weeks based on complement activation kinetics, creating a composite biomarker with staggered sensitivity windows that extends the predictive horizon beyond current single-timepoint approaches.

Proposed Validation

• Design: Prospective cohort, n≥150 SLE pregnancies (ACR/EULAR 2019 criteria), recruited at ≤14 weeks gestation
• Sampling: Monthly flow cytometry for P-C4d (anti-C4d-FITC on CD41+ gate) and serum sFlt-1/PlGF (Elecsys immunoassay) from weeks 12–36
• Primary endpoint: PE by ISSHP 2018 criteria
• Analysis: Joint longitudinal-survival model (shared random effects) with P-C4d level and sFlt-1/PlGF slope as time-varying covariates; time-dependent AUROC via inverse probability of censoring weighting
• Sample size justification: Based on 25% PE incidence in lupus pregnancies, 150 subjects yield ~38 events, sufficient for stable estimation of 4–6 parameters in the joint model (EPV >6)

Testable Predictions

1. P-C4d ≥15 mean fluorescence intensity (MFI) units above trimester-matched controls precedes PE diagnosis by median 10 weeks (IQR 6–14)
2. sFlt-1/PlGF slope >0.5 units/week over any 4-week window combined with P-C4d elevation yields positive predictive value ≥60% for PE within 8 weeks
3. The joint biomarker outperforms sFlt-1/PlGF ratio alone (ΔAUROC ≥0.08, p<0.05 by DeLong test)
4. P-C4d signal is independent of anti-dsDNA titer and C3/C4 serum levels (partial correlation <0.2 after adjustment)

Limitations

• Flow cytometric P-C4d measurement requires standardized protocols across sites; pre-analytical platelet activation during sample processing may confound results
• 150 subjects may be underpowered for subgroup analyses (e.g., by antiphospholipid antibody status or lupus nephritis history)
• Generalizability to non-SLE autoimmune pregnancies (e.g., APS without SLE) is not tested in this design
• Complement activation from concurrent lupus flares may reduce specificity for PE-specific C4d deposition
• sFlt-1/PlGF assay reference ranges differ between Elecsys and DELFIA platforms, limiting cross-study comparison

Clinical Significance

If validated, this composite biomarker could enable stratified surveillance protocols in lupus pregnancies: high-risk patients identified at 16–20 weeks would receive intensified monitoring (weekly BP, biweekly labs, fetal Doppler) and early aspirin/LMWH escalation, while low-risk patients could be managed with standard obstetric schedules. The 6–14 week lead time offers a clinically actionable window for prophylactic intervention that current angiogenic markers alone cannot provide.

LES AI • DeSci Rheumatology